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Abstract
BACKGROUND
A large number of adults with long-term type 1 diabetes are affected by
symmetrical peripheral neuropathy. These complications increase socioeconomic
expenses and diminish the individual quality of life. The 36-Item Short Form
Health Survey (SF-36) is a generic patient reported questionnaire, measuring
mental and physical health related quality of life. We hypothesized that diabetic
neuropathy would decrease physical and mental quality of life measured with
SF-36, and that clinical appearance may be associated with the decline.
AIM
To investigate if diabetic neuropathy would decrease physical and mental quality
of life measured with SF-36, and if clinical appearance may be associated with the
decline.
METHODS
Forty-eight adults [age 50 ± 9 years, 10 females, disease duration 32 (14-51) years]
with verified diabetic symmetrical peripheral neuropathy and 21 healthy
participants (age 51 ± 6 years, 6 females) underwent standardised nerve
WJD https://www.wjgnet.com February 15, 2019 Volume 10 Issue 287
subjects gave their informed
consent prior to inclusion.
Conflict-of-interest statement: Dr.
Brock reports grants from Aalborg
University, from Novo Nordisk
Scandinavia AS, from Empowering
Industry and Research EIR
Northern Jutland, grants from
Innovation Fund Denmark,
Individuals, Disease and Society,
Copenhagen, Denmark, during the
conduct of the study.
STROBE statement: The authors
have read the STROBE Statement-
checklist of items, and the
manuscript was prepared and
revised according to the STROBE
Statement-checklist of items.
Open-Access: This article is an
open-access article which was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution Non
Commercial (CC BY-NC 4.0)
license, which permits others to
distribute, remix, adapt, build
upon this work non-commercially,
and license their derivative works
on different terms, provided the
original work is properly cited and
the use is non-commercial. See:
http://creativecommons.org/licen
ses/by-nc/4.0/
Manuscript source: Unsolicited
manuscript
Received: January 2, 2019
Peer-review  started:  January  4,
2019
First decision: January 12, 2019
Revised: January 16, 2019
Accepted: February 11, 2019
Article in press: February 12, 2019
Published  online:  February  15,
2019
conduction testing and completed the SF-36 questionnaire. Furthermore, disease
duration, number of comorbidities, both diabetes related and nondiabetes
related, vibration perception threshold, number of hypoglycaemic events, HbA1c
and administration way of insulin was notified.
RESULTS
In comparison to healthy subjects, patients’ mental composite score was not
significantly diminished (51.9 ± 8.9 vs 53.1 ± 5.5, P = 0.558), while the physical
composite score was (46.3 ± 11.7 vs 54.6 ± 3.3, P = 0.002). As expected, the overall
physical health related symptoms in patients were associated to total number of
comorbidities (P < 0.0001), comorbidities relation to diabetes (P = 0.0002) and
HbA1c (P = 0.005) as well as comorbidities not related to diabetes (P = 0.0006).
CONCLUSION
The finding of this study emphasises the importance of focusing on quality of life
in adults with diabetes and especially in those with multiple comorbidities as
well as the possibility of HbA1c as a biomarker for severe complication.
Key words: Quality of life; 36-Item Short Form Health Survey (SF-36); Diabetes mellitus,
Type 1; Diabetic neuropathies; Comorbidity
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: In this study, we found a diminishment of physical domains more so than
mental components from the 36-Item Short Form Health Survey (SF-36), in 48 people
with type 1 diabetes and verified diabetic symmetrical peripheral neuropathy when
compared to 21 healthy controls. Additionally, this physical diminishment was
associated with increases in number of comorbidities and HbA1c. To our knowledge a
study of health related quality of life exclusively in people with type 1 diabetes and
diabetic symmetrical peripheral neuropathy compared to healthy age-matched controls
has not previously been performed, therefore these results are interesting for health care
professionals interested in the connection between neuropathy and patient experience.
Citation: Wegeberg AML, Meldgaard T, Hyldahl S, Jakobsen PE, Drewes AM, Brock B,
Brock C. Quantities of comorbidities affects physical, but not mental health related quality of
life in type 1 diabetes with confirmed polyneuropathy. World J Diabetes 2019; 10(2): 87-95
URL: https://www.wjgnet.com/1948-9358/full/v10/i2/87.htm
DOI: https://dx.doi.org/10.4239/wjd.v10.i2.87
INTRODUCTION
Diabetic symmetrical peripheral neuropathy is a frequent complication to type 1
diabetes, although the prevalence varies between countries[1]. The pathogenesis of
diabetic neuropathy is not fully understood; however, it is generally accepted to be a
consequence  of  hyperglycaemic  exposure  leading  to  activation  of  metabolic,
biochemical, inflammatory and immune mediated pathways. Clinically, neuropathy
can present itself both with and without symptoms, including decreased sensation
(numbness)  or  pain[2,3].  The severity of  peripheral  neuropathy is  associated with
incapacitating complications and a shorter life expectancy for the individual. On top
of this, research within the last years has focused increasingly on the physical as well
as mental burden of diabetes on quality of life.
It has become more and more acknowledged in clinical practice, to evaluate patient
centred outcomes in the measurement of disease burden, progression and treatment
outcome and how these impacts fundamental health related quality of life (HRQoL).
In an effort to standardise and examine HRQoL the development and validation of
instruments,  such  as  the  36-Item  Short  Form  Health  Survey  (SF-36),  enables
comparisons of different conditions between diseases, populations and countries[4].
The SF-36 has proved valid and useful in surveys of general and specific populations
comparing the relative burdens of diseases, and in differentiating the health benefits
produced  by  a  wide  range  of  treatments.  Previous  trans-sectional  studies  have
investigated the HRQoL status in diabetes; however, most studies were carried out in
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different types of diabetes and with mixed phenotypes. Thus, there is a knowledge
gap in characterising the HRQoL in a population with type 1 diabetes and diabetic
symmetrical peripheral neuropathy[5,6].
We hypothesized that the presence of diabetic symmetrical peripheral neuropathy
would decrease the individual physical and mental quality of life. Thus, the aim of
this study was to compare the HRQoL in adults with type 1 diabetes as compared
with healthy age-matched controls using the SF-36 questionnaire.  In addition, in
patients  we wanted to investigate  associations between HRQoL and:  (1)  disease
duration; (2) number of comorbidities, both diabetes related and non-diabetes related;
(3) vibration thresholds; (4) nerve conduction velocity of the efferent median nerve;
(5) nerve conduction velocity of the afferent sural nerve; (6) number of hypoglycaemic
events; (7) glycaemic state; and (8) the use of insulin pen or pump.
MATERIALS AND METHODS
Subjects
The  study  comprised  baseline  observations  of  48  people  with  long-term type  1
diabetes and verified diabetic symmetrical peripheral neuropathy recruited at the
Department of Endocrinology, Aalborg University Hospital, Denmark from June 2014
to March 2016,  as  part  of  a  clinical  trial  investigating the effect  of  liraglutide on
neuropathy (TODINELI trial, (EUDRA CT 2013-004375-12). The local ethics committee
approved the study protocols (N-20130077). Inclusion criteria were adults (> 18 years)
with type 1  diabetes  for  a  minimum duration of  two years  and diabetic  sensory
neuropathy verified by nerve conduction velocity testing. Additional criteria has been
described elsewhere[7]. In comparison, 21 adult healthy, age-matched, participants
were recruited for comparison. Informed consent was obtained from all individual
participants included in the study.
Health quality and pain perception questionnaires
To assess HRQoL, participants completed the SF-36[8-10]. Even though it is not specific
for diabetes,  it  has been validated and the components are relevant to assess the
symptom  burden  experienced  in  diabetes[11].  The  SF-36  was  developed  as  a
multipurpose eight-scale profile of functional health and well-being scores (physical
functioning, role limitation due to physical problems, bodily pain, general health,
vitality, social functioning, role limitation due to emotional problems, and mental
health),  and  two  summary  scores  (physical  component  summary  and  mental
component summary), to explain variations in patient outcomes, covering 4 wk prior
to the test[8,12]. Scores from the 36 items are transformed to a 0-100 scale with higher
scores equals better quality of life[6,12]. A greater than five point change on this scale is
considered clinically significant[6].
Protocol
Health care professionals obtained information about disease duration, comorbidities
and way of insulin intake. Vibration perception threshold was measured using a
biothesiometer (Bio-Medical Instruments, Newbury, OH, United States) on the distal
plantar surface of the big toes. Peripheral nerve conduction testing of the efferent
median  and  afferent  sural  nerves  was  evaluated  at  the  elbow  and  the  ankle,
respectively, with plastic bar electrodes at skin temperatures above 32 °C. A blood
sample was taken for measurement of HbA1c (IFCC) and number of hypoglycaemic
events was registered in a patient diary two days prior to the study day.
Statistical analysis
The statistical methods of this study were reviewed by all the authors. Normally
distributed data  was  reported as  means  and standard deviations,  non-normally
distributed data as median and interquartile range while categorical data is provided
as  a  percentage.  An  independent-sample  t-test  was  undertaken  to  determine
differences in HRQoL between the two groups.  For parametric data,  a Pearson’s
correlation tests were performed to investigate associations between HRQoL and
disease duration, HbA1c, average vibration thresholds and nerve conduction velocity
for  the efferent  median and sural  nerves.  For nonparametric  data,  a  Spearman’s
correlation tests were performed to investigate associations between HRQoL and
number of hypoglycaemic events, total number of comorbidities, diabetes related and
non  diabetes  related  comorbidities.  Diabetes  related  includes  hypertension,
retinopathy, pain, albuminuria,  erectile dysfunction and cardiovascular diseases.
Non-diabetes  related  includes  hypercholesterolemia,  thrombose  prophylaxis,
operations, reflux, arthritis and arthroses, asthma and allergies, metabolic diseases,
vitamin deficiencies and more. Additionally, an independent samples t-test was run
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to determine if there was a difference between people with diabetes who used insulin
pens or pump.
RESULTS
A total  of  48  people  with  type  1  diabetes  and  21  adult  heathy  volunteers  were
included in and completed the study. The demographic distribution is shown in Table
1 and displays no notable difference in demographic characteristic between the two
groups.
Comparison between type 1 diabetics and healthy controls
As seen in Figure 1, when diabetes was present, a numerical decline was observed in
every SF-36 domain, compared to healthy subject. Significant differences were found
on physical functioning (78.6 ± 27.7 vs 96.7 ± 6.2, P = 0.005), role limitation due to
physical problems (82.4 ± 31.7 vs 100 ± 0, P = 0.01), general health (64.4 ± 24.5 vs 85.3 ±
13.1, P < 0.001), vitality (65.5 ± 23.9 vs 78.1 ± 13.9, P = 0.03), role limitations due to
personal or emotional problems (87.0 ± 27.3 vs  100 ± 0, P =  0.03) and the physical
composite score (46.3 ± 11.7 vs 54.6 ± 3.3, P = 0.002). However, no significance was
found lookig at bodily pain (76.2 ± 24.34 vs 87.3 ± 17.7, P = 0.07), social functioning
(91.9 ± 13.9 vs 95.2 ± 15.0, P = 0.39), mental health (81.2 ± 16.9 vs 86.7 ± 13.6, P = 0.20)
and the mental composite score (51.9 ± 8.9 vs 53.1 ± 5.5, P = 0.56).
Associations
There was a negative association between the physical composite score of SF-36 and
number of comorbidities (r = -0.62, P < 0.001), both diabetes (r = -0.53, P = 0.018) and
non-diabetes related (r = -0.51, P < 0.001), and HbA1c level (r = -0.41, P = 0.005), as can
be seen in Figure 2. However, one of these were associated with the mental composite
score of SF-36 (P > 0.05).
Additionally,  physical  parameters  of  physical  function,  role  limitation due to
physical health, bodily aim and general health were all associated to and number of
comorbidities (P < 0.01), both diabetes (P < 0.03) and non-diabetes related (P < 0.02),
while only physical function and bodily pain were associated to HbA1c (P < 0.02).
More detail can be found in Table 2.
Disease duration, vibration threshold, nerve conduction velocity of the efferent
median nerve and the afferent sural nerve, and number of hypoglycaemic events were
not  associated  with  HRQoL  scores.  Additionally,  there  was  no  difference  in
symptoms between people using standard insulin pens and people using insulin
pumps.
DISCUSSION
This study partly confirms our hypothesis, as in particular physical domains and not
mental  domains  were  negatively  affected  in  people  with  diabetes  and  diabetic
symmetrical peripheral neuropathy, potentially limiting the patients in their daily
work and social activities. This emphasizes the importance of assessing HRQoL in
long-term diabetes. Additionally, increased numbers of comorbidities and high levels
of HbA1c, were associated with decreased HRQoL scores.
Decreased physical HRQoL
Decreased HRQoL is of great importance. It has been shown that a 1 point decrease in
physical functioning and physical composite scores equals an 9% increase in mortality
risk, a 4% increase in the risk of hospitalization within six months, and a 12% increase
in the risk of being unable to work[13]. As preventive medicine may be initiated in
order to delay or reverse the negative impact on self-assessed health, the importance
of assessing HRQoL is essential in monitoring the self-assessed burden of diabetes.
Decreased HRQoL in people with diabetes has previously been shown in studies from
Croatia, Norway and Australia[5,6,14,15]. However, the previously investigated cohorts
consisted of both type 1 and type 2 diabetes. As patients with type 2 diabetes often
appear with other comorbidities and stereotypical life style, this can have negative
impact on the combined HRQoL[14]. In contrast, a study by Jacobson et al[16] studied
HRQoL in people with type 1 diabetes over an average of 23 years and found no
decrease in HRQoL scores over time. The present study we looked into HRQoL in
patients  with  type  1  diabetes  compared  to  healthy  and  we  found  numerically
decreased and clinically relevant declines in HRQoL for all sub-scores, except social
functioning and a most significant decrease in the physical components. This finding,
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Table 1  Demographics
Type 1 diabetes (n = 48) Healthy controls (n = 21) P value
Gender, male n (%) 38 (79) 15 (71) 0.48
Age 50 ± 9 51 ± 6 0.53
Height 178.4 ± 1.2 179.9 ± 1.9 0.51
Weight 90.0 ± 2.3 87.3 ± 4.5 0.56
Right handed n (%) 41 (85) 17 (81) 0.64
Smoking n (%) 10 (21) 4 (19) 0.87
Disease duration 32 (14-51)
HbA1c (IFCC), mmol/mol 65.5 ± 9.7
Numerical data was compared with a t-test and categorical data with a χ2-test.
related to the mixed cohorts,  is possibly because people with type 1 diabetes are
found  in  all  social  groups,  and  hence  also  in  all  social  groups  with  larger
psychological  resources in comparison to people with type 2 diabetes.  Contrary,
compared with the study by Jacobson et al[16], we only had a cross-sectional look at
HRQoL and therefore do not know the long-term ramifications for our patient group.
No decrease in mental HRQoL in people with severe diabetic neuropathy
Mental health has received increased recognition in recent years. Studies have shown
that people with type 1 diabetes have a three-fold rate of depression in comparison to
the general population. However, in the current study we did not find a significant
decreased mental composite score, nor in the mental domains of social functioning
and mental health.
Comorbidities decrease HRQoL
The presence of physical disabling diabetic complications such as cardiovascular
events, gastrointestinal dysfunction and neuropathy with or without pain, have been
shown to decrease HRQoL[6,14,17,18]. In a cohort of people with type 1 diabetes who were
followed  over  6  years,  disease  duration  and  the  presence  of  complications
convincingly  decreased  the  physical  composite  scores[19],  and  the  presence  of
neuropathy in type 1 diabetes negatively influenced the physical composite score[20],
in line with the impact on the sensory and motor system. Additionally, a study over
17 years in people with type 1 diabetes showed that development of microvascular
complications significantly decreased HRQoL[16]. We showed no association between
the severity of neuropathy and the HRQoL scores,  nor with disease severity and
duration.  These  findings  are  plausibly  biased  by  the  fact  that  all  patients  were
included based on severe polyneuropathy. In a study assessing HRQoL in chronic
diseases  with  the  presence  of  comorbidities,  HRQoL  was  decreased  due  to  the
chronicity, but this was exaggerated as the number of comorbidities increased[21]. In
particular, Bjorner et al[13] showed that number of comorbidities did not affect mental
composite score. The current finding where HRQoL decreased with an increased
number of comorbidities,  needs to be considered when preventive medicine and
adequate disease management is planned.
HbA1C decreases HRQoL
Even though HbA1c only indicates the preceding 3-mo’ glycaemic status, it provides
patients  and  clinicians  with  an  objective  measure.  Mellerio  et  al[22]  studied  the
association between HbA1C and HRQoL in adult people with childhood onset type 1
diabetes.  They  concluded  that  no  metabolic  parameters,  including  HbA1c,  was
predictive of HRQoL, thereby indicating that social impact was more important than
glycaemic control for the well-being[22]. In contrast, the mean disease duration in this
cohort was 32 years and we showed that HRQoL decreased as HbA1c increased,
which may reflect lack of life-long tight glucose control. On the other hand, this could
also reflect the impact of neuropathy and its effect on the ability to tightly control
glucose, thus pointing to HbA1c as a potential marker of complications and not solely
of glucose control. The data on the association between HRQoL and hypoglycaemia is
conflicting. Hypoglycaemic events affects negatively on the individual health, and
quality of  life[20].  However,  in a larger cohorts  of  people with type 1 diabetes no
association  between hypoglycaemia  and HRQoL was  shown[20,23].  In  contrast,  in
younger individuals an association between role limitations due to physical problems
and hypoglycaemic  events  was  reported[18].  Unfortunately,  in  the  current  study,
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Figure 1
Figure 1  Comparison of mean SF-36 scores with confidence intervals for people with type 1 diabetes (●) and
healthy participants (▲).
hypoglycaemic episodes were only sparsely recorded (48 h), and therefore it was not
surprisingly,  that  we  did  not  find  any  association  between  the  number  of
hypoglycaemic events and HRQoL.
Insulin  treatment  is  the  core  of  glycaemic  control  and management  of  type  1
diabetes  and  with  the  rise  of  new  technologies  such  as  continuous  glucose
measurements combined with improved treatment the last couple of years, this has
become easier for the patients. Surprisingly, Hart et al[17]  showed that continuous
insulin treatment decreased the mental composite score, due to the stress of regular
blood glucose monitoring. Such findings were not supported by this study, as no
differences in HRQoL were shown between people using insulin pens or pump.
Limitations
This study was not without limitations. Firstly, this study was conducted in a well-
defined, middle-aged cohort with verified severe diabetic symmetrical peripheral
neuropathy and thus  the  results  cannot  be  directly  generalised  to  other  patient
groups. Additionally, these were compared with healthy individuals, and therefore
the effects measured may be skewed due to the effect of diabetes alone on SF-36.
Secondly, we used the SF-36 to measure HRQoL assessments. Future studies may use
the diabetes specific quality of life questionnaires and potentially add more insight
into  diabetes  HRQoL.  Lastly,  it  would  have  been  interesting  to  study  if
hyperglycaemic events were associated to HRQoL in this cohort.
Conclusion
In  summary,  as  hypothesised  this  study  showed  a  decrease  in  the  physical
components of the HRQoL in a well-defined cohort of people with type 1 diabetes and
severe diabetic symmetrical peripheral neuropathy. To our surprise, no associations
were  found  in  the  mental  components.  Furthermore,  decreased  HRQoL  was
associated to number of co-morbidities and dysregulated glycaemic control, but not to
the severity of neuropathy. This emphasises the importance of considering quality of
life  in  people  with  diabetes,  especially  in  those  with  multiple  comorbidities.
Furthermore, it is important to consider HbA1c as a biomarker for complication and
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Figure 2
Figure 2  Correlations between physical and mental composite scores, HbA1c and comorbidities.
thereby indirectly for quality of life.
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Table 2  Associations between 36-Item Short Form Health Survey and HbA1c, comorbidities, both diabetes and non-diabetes related in
patients with type 1 diabetes
HbA1c All omorbidities Diabetes elated Non-diabetes related
Physical functioning r -0.51 -0.58 -0.42 -0.52
p < 0.01 < 0.01 < 0.01 < 0.01
Role limitation physical health r -0.44 -0.33 -0.38
p < 0.01 0.03 0.01
Bodily pain r -0.34 -0.48 -0.43 -0.38
p 0.02 < 0.01 < 0.01 0.01
General health r -0.41 -0.34 -0.36
p < 0.01 0.02 0.02
Diabetes related comorbidities includes hypertension, retinopathy, pain, albuminuria, erectile dysfunction and heart and vessel diseases. Non-diabetes
related comorbidities includes hypercholesterolemia, thrombose prophylaxis, operations, reflux, arthritis and arthroses, asthma and allergies, metabolic
diseases, vitamin deficiencies and more.
ARTICLE HIGHLIGHTS
Research background
Diabetic symmetrical peripheral neuropathy is a frequent complication to type 1 diabetes and is
associated to incapacitating complication and decreased lifespan,  possibly affecting health
related quality of life (HRQoL). The 36-Item Short Form Health Survey (SF-36) is a generic
patient reported questionnaire, which can be used to evaluate mental and physical HRQoL in
patients with diabetes.
Research motivation
HRQoL is an increasingly acknowledged method in clinical practice, to evaluate patient centred
outcomes in the measurement of disease burden, progression and treatment outcome.
Research objective
To investigate  if  diabetic  neuropathy  would  decrease  physical  and  mental  quality  of  life
measured with SF-36, and if clinical appearance may be associated with the decline.
Research methods
Baseline data of standardised nerve conduction and SF-36 questionnaire as well as information
on disease  duration,  number  of  comorbidities,  vibration  perception  threshold,  number  of
hypoglycaemic events, HbA1c and administration way of insulin was collected from 48 adults
with verified diabetic symmetrical peripheral neuropathy and 21 healthy participants as part of a
clinical trial.
Research results
People with diabetic symmetrical peripheral neuropathy had a significantly decreased physical
score, but not mental score compared with healthy. Furthermore, this decrease in physical score
was associated with total number of comorbidities, comorbidities relation to diabetes and HbA1c
as well as comorbidities not related to diabetes.
Research conclusions
HRQoL is an important tool for evaluate patient centred outcomes in people with diabetes and is
decreased with diabetic symmetrical peripheral neuropathy but also with increase in symptoms
and suboptimal long-term glucose measures.
Research perspectives
HRQoL is an informative measure for use in investigation of diabetes and related neuropathy or
symptoms in the future.
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